| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 111.05 | 0.4% | 23.3% |
| Total Income | 111.95 | 0.1% | 24.0% |
| Expenditure | 93.50 | 1.4% | 20.3% |
| PBT | 18.45 | 8.4% | 47.0% |
| Net Profit | 14.12 | 18.4% | 66.9% |
| OPM | 22.83% | 1.14pp | 17.27pp |
| NPM | 12.61% | 1.95pp | 3.24pp |
| EPS | 13.60 | 18.4% | 66.9% |
Kwality Pharmaceuticals Reports 32% YoY Revenue Growth in H1 FY26, Expects Continued Momentum in Q3
13 Nov 2025 · 13 Nov 2025, 02:12 pm
Summary
Kwality Pharmaceuticals Ltd delivered a strong performance in the first half of FY26, with consolidated revenue rising 32% YoY to 224 crore. The growth was driven by robust sales of registered products across key international markets. EBITDA increased by 35% YoY to 250 crore, reflecting improved scale and mix optimization. Net profit rose from 17 cr in H1FY25 to 26 cr in H1FY26. The company accelerated its R&D and clinical initiatives and advanced its strategic capex program. KPL expects continued growth momentum in Q3 FY26, driven by higher order inflows, new product launches, and scale-up across international markets.
Key Highlights
- 1
Consolidated revenue rose 32% YoY to 224 crore in H1 FY26
- 2
EBITDA increased by 35% YoY to 250 crore in H1 FY26
- 3
Net profit rose from 17 cr in H1FY25 to 26 cr in H1FY26
- 4
KPL accelerated its R&D and clinical initiatives
- 5
Strategic capex program advanced with expansion underway at Biologics and Oncology facilities
- 6
Hormone manufacturing facility construction and validation work progressing as scheduled
- 7
Company generated a cash surplus of approximately 230 crore during the quarter
- 8
Multiple new product registrations received during the quarter
- 9
Revenue for Q3 FY26 expected to be around 2140 crore
- 10
EBITDA projected to increase sequentially in Q3 FY26
- 11
Management confident of exceeding 2500 crore revenue target for FY26
- 12
Company has five state-of-the-art manufacturing facilities approved by leading global regulators
Management Comments
Ramesh Arora
KPL delivered a strong performance in the first half of FY26, with consolidated revenue rising 32% YoY, from 170 crore in H1 FY25 to 224 crore in H1 FY26. The growth was driven by robust sales of registered products across key international markets, supported by the expanding product portfolio and enhanced geographic reach. EBITDA increased by 35% YoY, from 37 crore in H1 FY25 to 250 crore in H1 FY26, reflecting improved scale and mix optimization. EBITDA margins improved to 22.5% from 22.0% last quarter, Net profit rose from 17 cr in H1FY25 to 26 cr in H1FY26 supported by operational efficiencies and disciplined cost management initiatives.
Informational and educational content only. Not investment advice.